cagrilintide tirzepatide combination trial Efficacy and safety of co-administered once-weekly 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 REDEFINE 1 Trial Finds Cagrilintide–Semaglutide

Zhang et al., 2022)

MT-2:Available at 10mg

The FDA just put GHK-Cu injections on its Category 2 restricted compounding list in April of 2026 while the Pharmacy Compounding Advisory Committee takes a closer look at its safety profile

The oral activity of BPC-157 in rodent models is particularly distinctive and has motivated research into its gastrointestinal biology and the mechanisms through which orally administered peptide produces systemic repair effects despite the proteolytic environment of the gastrointestinal tract

Evidence for disrupted copper availability in human spinal cord supports CuII(atsm) as a treatment option for sporadic cases of ALS

Cell Metabolism , 24(2), 269282